Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

One-hour Troponin in a Low-prevalence Population of Acute Coronary Syndrome

Conditions:   Non-ST Elevation Myocardial Infarction;   Acute Coronary Syndrome;   Angina, Unstable;   NSTEMI - Non-ST Segment Elevation MI
Intervention:   Procedure: 1-hour hs-cTnT
Sponsors:   Oslo University Hospital;   University of Oslo
Recruiting - verified December 2016

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS

Condition:   ST Elevation Myocardial Infarction
Interventions:   Drug: DLBS1033;   Drug: Placebo;   Drug: Standard therapy
Sponsors:   Dexa Medica Group;   Binawaluya Cardiac Hospital, Jakarta
Recruiting - verified November 2016

Trial of MiStent Compared to Xience in Japan

Condition:   Coronary (Artery); Disease
Interventions:   Device: MiStent (MT005) Coronary Artery Stent;   Device: Xience Coronary Artery Stent
Sponsors:   Micell Technologies;   Cardialysis BV;   ClinLogix. LLC
Recruiting - verified November 2016

The Accuracy of the Mini RELF Device for the Diagnosis of an Acute Coronary Artery Occlusion.

Conditions:   Chest Pain;   ST Elevation Myocardial Infarction
Intervention:   Device: Diagnostic accuracy of Mini Relf Device
Sponsor:   University Ghent
Recruiting - verified December 2016

Imaging of periOP Lung Injury

Conditions:   Acute Lung Injury;   Chronic Obstructive Pulmonary Disease (COPD)
Intervention:   Radiation: AxV-128/Tc SPECT-CT imaging
Sponsors:   Columbia University;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified November 2016

Early Versus Late Sustained Low Efficiency Dialysis in Critically Ill Cirrhotics With Septic Shock and Acute Kidney Injury

Condition:   Cirrhotics With Septic Shock and Acute Kidney Injury
Interventions:   Biological: Early SLED;   Biological: Late SLED
Sponsor:   Institute of Liver and Biliary Sciences, India
Recruiting - verified October 2016

Diaphragmatic Ultrasound to Predict NIV Outcome in Patients With De-novo ARF

Condition:   Acute Respiratory Failure
Sponsor:   Policlinico Universitario Agostino Gemelli
Recruiting - verified November 2016

The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III

Conditions:   Cardiac Arrest;   Renal Failure;   Respiration Failure;   Myocardial Infarction;   Severe Sepsis
Intervention:   Device: Automatic RR Measurement
Sponsor:   Philips Healthcare
Recruiting - verified November 2016

Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease

Condition:   Kawasaki Disease
Intervention:   Drug: Canakinumab
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified November 2016

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France

Condition:   Atrial Fibrillation
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Vitamin K antagonists;   Drug: dabigatran (Pradaxa)
Sponsor:   Bayer
Recruiting - verified November 2016

L-Citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects

Condition:   Acute Lung Injury
Interventions:   Drug: L-citrulline;   Other: Placebo
Sponsor:   Asklepion Pharmaceuticals, LLC
Recruiting - verified September 2016

Interest of CARE Rule to Exclude the Hypothesis of an Acute Coronary Syndrome Without Bioassay - ICARE

Condition:   Chest Pain
Intervention:   Other: CARE Rule
Sponsor:   University Hospital, Angers
Recruiting - verified June 2016

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Conditions:   B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified August 2016

Cardiopulmonary Effects of Bronchoalveolar Wash on Patients With Acute Respiratory Distress Syndrome

Condition:   Bronchioalveolar Lavage
Intervention:   Procedure: Bronchoalveolar Lavage
Sponsor:   University Hospital, Limoges
Recruiting - verified November 2016

Peak Systolic Global Longitudinal Strain and Low Cardiac Output Syndrome After Cardiac Surgery

Condition:   Low Cardiac Output Syndrome After Adult Cardiac Surgery
Intervention:   Procedure: Cardiac surgery
Sponsor:   University Hospital of Liege
Completed - verified June 2016

Prophylactic Non-invasive Ventilation During Surgical Procedure in Rhythmology

Conditions:   Cardiac Electrophysiology;   Anesthesia;   Acute Respiratory Failure
Interventions:   Other: non invasive ventilation;   Other: Standard oxygen therapy with facial mask
Sponsor:   University Hospital, Grenoble
Not yet recruiting - verified December 2016

The Physiological Impact of CTO PCI on Coronary Pressure Measurements and Correlation in Donor Vessel

Conditions:   Acute Coronary Syndrome;   Coronary Artery Disease
Sponsor:   Basildon and Thurrock University Hospitals NHS Foundation Trust
Recruiting - verified December 2016

Clinical Performance Evaluation of AQT90 FLEX TnI and TnT

Condition:   Myocardial Infarction
Sponsor:   Radiometer Medical ApS
Recruiting - verified November 2016

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Recruiting - verified November 2016

Antiplatelet Therapy in Acute Coronary Syndrome(ACS). Safety and Efficacy of Switching Antiplatelet

Condition:   Acute Coronary Syndrome
Sponsor:   Fundación Pública Andaluza Progreso y Salud
Recruiting - verified December 2016

Impact of the Obstructive Sleep Apnea Syndrome (OSAS) on the Ventricular Remodeling After Acute Myocardial Infarction

Condition:   Recent Acute Myocardial Infarction
Interventions:   Other: Without Obstructive Sleep Apnea (syndrome);   Other: Mild or moderate Obstructive Sleep Apnea (syndrome);   Other: Severe Obstructive Sleep Apnea (syndrome);   Device: CPAP
Sponsor:   University Hospital, Montpellier
Recruiting - verified November 2016

EndoTic - Endothelium and Ticagrelor

Condition:   Acute Coronary Syndrome (ACS)
Intervention:   Drug: Ticagrelor vs Clopidogrel
Sponsors:   Fundación Investigación Sanitaria en León;   AstraZeneca
Completed - verified November 2016

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified October 2016

Decisional Quality for Patients With Coronary Artery Disease

Condition:   Coronary Artery Disease
Interventions:   Behavioral: Decision Aid;   Behavioral: CAD Education
Sponsors:   University of California, San Francisco;   University of Missouri, Kansas City;   Mid America Heart Institute;   Emory University;   Massachusetts General Hospital
Enrolling by invitation - verified December 2016

Essential Hypotension and Adaptability Registry

Conditions:   Blood Pressure;   Depression;   Panic Attack;   Fibromyalgia;   POTS;   Inappropriate Sinus Tachycardia;   Coronary Heart Disease;   Acute Coronary Syndrome (ACS);   Acute Myocardial Infarction (AMI);   Cerebrovascular Disease (CVD);   Transient Ischemic Attack (TIA);   Atrial Fibrillation;   Diabetes Mellitus;   Cancer;   Systolic Heart Failure;   Diastolic Heart Failure;   Chronic Fatigue Syndrome;   Syncope;   Vasovagal Syncope
Sponsor:   CES University
Recruiting - verified November 2016

Screening for Abdominal Aortic Aneurysm Using a Portable Transthoracic Echocardiography Among Patients With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Sponsor:   HaEmek Medical Center, Israel
Completed - verified December 2016

ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial

Condition:   End Stage Renal Failure on Dialysis
Interventions:   Drug: Spironolactone;   Drug: Placebo
Sponsors:   University Hospital, Brest;   Central Hospital, Nancy, France;   Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified November 2016

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab;   Drug: Placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified November 2016

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia
Interventions:   Other: Antitumor Drug Screening Assay;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Other: Pharmacological Study;   Drug: Ponatinib Hydrochloride;   Drug: Sorafenib Tosylate;   Drug: Sunitinib Malate
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified December 2016

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Condition:   Non-Malignant
Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   medac GmbH;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2016

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Conditions:   Deep Vein Thrombosis;   Venous Thrombosis;   Postphlebitic Syndrome;   Venous Thromboembolism;   Post Thrombotic Syndrome
Intervention:   Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors:   Washington University School of Medicine;   McMaster University;   Ontario Clinical Oncology Group (OCOG);   National Heart, Lung, and Blood Institute (NHLBI);   BSN Medical Inc;   Genentech, Inc.;   Medtronic - MITG;   Boston Scientific Corporation;   Mid America Heart Institute;   Society of Interventional Radiology Foundation;   Massachusetts General Hospital
Active, not recruiting - verified November 2016

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances

Conditions:   Immunosuppression;   Leukemia
Intervention:   Device: SOLEX 300i Stem Cell Selection
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified November 2016

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Conditions:   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Systemic Amyloidosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenström Macroglobulinemia
Interventions:   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
Active, not recruiting - verified November 2016

Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies

Conditions:   Hodgkin Lymphoma;   Lymphocytic Leukemia;   Mixed Cell Leukemia;   Myelodysplastic Syndrome;   Non Hodgkin's Lymphoma;   CML;   ALL;   AML;   Lymphoma
Intervention:   Procedure: Stem cell transplantation
Sponsor:   National Cancer Institute (NCI)
Completed - verified May 2015